Jack C Yalowich, PhD

Jack Yalowich


College of Pharmacy


College of Pharmacy

Academic Title


Research Program

Translational Therapeutics

Research Interest

DNA Damage, Leukemia, Carcinoma, Ehrlich Tumor, Leukemia, Erythroblastic, Acute, Leukemia L1210, Oxidative stress, DNA Breaks, Double-Stranded, Leukemia, Myeloid, Breast Cancer, Cancer

Jack Yalowich, PhD, is a member of the Translational Therapeutics Program at OSUCCC – James, where his research focuses on therapeutic treatment and prevention of cancers.

In particular, he is exploring how to improve ability of the clinically effective anticancer agent etoposide (VP-16) in cancer treatment as well as how to prevent benzene leukemogenesis.

One of his recent studies revealed that the molecule, tripartite motif protein 72 (TRIM72) could be a therapeutic target for patients with injured lungs.

Dr. Yalowich has co-authored many articles in well-respected publications, including Journal of Pharmacology and Experimental Therapeutics, Bioorganic & Medicinal Chemistry, Biochemical Pharmacology and Phytochemistry.

Office Location

532 Parks Hall

500 W 12th Ave, Columbus, OH 43210




Back to Researcher Search

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Search for Clinical Trials

Find a Scientific Publication